Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics

BACKGROUND: A low skeletal muscle mass (SMM) has been associated with increased toxicity and shorter survival in cancer patients treated with capecitabine, an oral prodrug of 5‐fluorouracil (5‐FU). Capecitabine and its metabolites are highly water‐soluble and, therefore, more likely to distribute to...

Descripción completa

Detalles Bibliográficos
Autores principales: Molenaar‐Kuijsten, Laura, Jacobs, Bart Albertus Wilhelmus, Kurk, Sophie Alberdine, May, Anne Maria, Dorlo, Thomas Petrus Catharina, Beijnen, Jacob Hendrik, Steeghs, Neeltje, Huitema, Alwin Dagmar Redmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290233/
https://www.ncbi.nlm.nih.gov/pubmed/34121365
http://dx.doi.org/10.1002/cam4.4038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290233/
https://www.ncbi.nlm.nih.gov/pubmed/34121365
http://dx.doi.org/10.1002/cam4.4038

Ejemplares similares